Z-drug for schizophrenia: A systematic review and meta-analysis

Taro Kishi, Ken Inada, Yuki Matsui, Nakao Iwata

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

No systematic reviews and meta-analyses on the use of Z-drug for schizophrenia are available. Randomized, placebo-controlled, or non-pharmacological intervention-controlled trials published before 03/20/2017 were retrieved from major healthcare databases and clinical trial registries. A meta-analysis including only randomized, placebo-controlled trials was performed. Efficacy outcomes were measured as improvement in overall schizophrenia symptoms, total sleep time, and wake after sleep onset. Safety/acceptability outcomes were discontinuation rate and individual adverse events. Four trials [1 alpidem placebo-controlled study (n=66), 2 eszopiclone placebo-controlled studies (n=60), and 1 eszopiclone, shallow needling-controlled study (n=96)] were identified. The meta-analysis showed no significant differences in any outcome between pooled Z-drug and placebo treatment groups. For individual studies, alpidem was superior to placebo in improving the overall schizophrenia symptoms. One of the eszopiclone studies showed that eszopiclone was superior to placebo in improving the Insomnia Severity Index scores. Another eszopiclone study showed that eszopiclone did not differ from shallow needling therapy in improving both schizophrenia- and insomnia-related symptoms. Although this study failed to show significant benefits for the use of Z-drug in the treatment of schizophrenia, it showed that short-term use of eszopiclone is an acceptable method for treating persistent insomnia among these patients.

Original languageEnglish
Pages (from-to)365-370
Number of pages6
JournalPsychiatry Research
Volume256
DOIs
Publication statusPublished - 01-10-2017

Fingerprint

Meta-Analysis
Schizophrenia
Placebos
Pharmaceutical Preparations
Sleep Initiation and Maintenance Disorders
Sleep
Eszopiclone
Registries
Therapeutics
Randomized Controlled Trials
Clinical Trials
Databases
Delivery of Health Care
Safety

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Kishi, Taro ; Inada, Ken ; Matsui, Yuki ; Iwata, Nakao. / Z-drug for schizophrenia : A systematic review and meta-analysis. In: Psychiatry Research. 2017 ; Vol. 256. pp. 365-370.
@article{d3b0a612c94e4ebc94a4b22013c2e5c8,
title = "Z-drug for schizophrenia: A systematic review and meta-analysis",
abstract = "No systematic reviews and meta-analyses on the use of Z-drug for schizophrenia are available. Randomized, placebo-controlled, or non-pharmacological intervention-controlled trials published before 03/20/2017 were retrieved from major healthcare databases and clinical trial registries. A meta-analysis including only randomized, placebo-controlled trials was performed. Efficacy outcomes were measured as improvement in overall schizophrenia symptoms, total sleep time, and wake after sleep onset. Safety/acceptability outcomes were discontinuation rate and individual adverse events. Four trials [1 alpidem placebo-controlled study (n=66), 2 eszopiclone placebo-controlled studies (n=60), and 1 eszopiclone, shallow needling-controlled study (n=96)] were identified. The meta-analysis showed no significant differences in any outcome between pooled Z-drug and placebo treatment groups. For individual studies, alpidem was superior to placebo in improving the overall schizophrenia symptoms. One of the eszopiclone studies showed that eszopiclone was superior to placebo in improving the Insomnia Severity Index scores. Another eszopiclone study showed that eszopiclone did not differ from shallow needling therapy in improving both schizophrenia- and insomnia-related symptoms. Although this study failed to show significant benefits for the use of Z-drug in the treatment of schizophrenia, it showed that short-term use of eszopiclone is an acceptable method for treating persistent insomnia among these patients.",
author = "Taro Kishi and Ken Inada and Yuki Matsui and Nakao Iwata",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.psychres.2017.06.063",
language = "English",
volume = "256",
pages = "365--370",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",

}

Z-drug for schizophrenia : A systematic review and meta-analysis. / Kishi, Taro; Inada, Ken; Matsui, Yuki; Iwata, Nakao.

In: Psychiatry Research, Vol. 256, 01.10.2017, p. 365-370.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Z-drug for schizophrenia

T2 - A systematic review and meta-analysis

AU - Kishi, Taro

AU - Inada, Ken

AU - Matsui, Yuki

AU - Iwata, Nakao

PY - 2017/10/1

Y1 - 2017/10/1

N2 - No systematic reviews and meta-analyses on the use of Z-drug for schizophrenia are available. Randomized, placebo-controlled, or non-pharmacological intervention-controlled trials published before 03/20/2017 were retrieved from major healthcare databases and clinical trial registries. A meta-analysis including only randomized, placebo-controlled trials was performed. Efficacy outcomes were measured as improvement in overall schizophrenia symptoms, total sleep time, and wake after sleep onset. Safety/acceptability outcomes were discontinuation rate and individual adverse events. Four trials [1 alpidem placebo-controlled study (n=66), 2 eszopiclone placebo-controlled studies (n=60), and 1 eszopiclone, shallow needling-controlled study (n=96)] were identified. The meta-analysis showed no significant differences in any outcome between pooled Z-drug and placebo treatment groups. For individual studies, alpidem was superior to placebo in improving the overall schizophrenia symptoms. One of the eszopiclone studies showed that eszopiclone was superior to placebo in improving the Insomnia Severity Index scores. Another eszopiclone study showed that eszopiclone did not differ from shallow needling therapy in improving both schizophrenia- and insomnia-related symptoms. Although this study failed to show significant benefits for the use of Z-drug in the treatment of schizophrenia, it showed that short-term use of eszopiclone is an acceptable method for treating persistent insomnia among these patients.

AB - No systematic reviews and meta-analyses on the use of Z-drug for schizophrenia are available. Randomized, placebo-controlled, or non-pharmacological intervention-controlled trials published before 03/20/2017 were retrieved from major healthcare databases and clinical trial registries. A meta-analysis including only randomized, placebo-controlled trials was performed. Efficacy outcomes were measured as improvement in overall schizophrenia symptoms, total sleep time, and wake after sleep onset. Safety/acceptability outcomes were discontinuation rate and individual adverse events. Four trials [1 alpidem placebo-controlled study (n=66), 2 eszopiclone placebo-controlled studies (n=60), and 1 eszopiclone, shallow needling-controlled study (n=96)] were identified. The meta-analysis showed no significant differences in any outcome between pooled Z-drug and placebo treatment groups. For individual studies, alpidem was superior to placebo in improving the overall schizophrenia symptoms. One of the eszopiclone studies showed that eszopiclone was superior to placebo in improving the Insomnia Severity Index scores. Another eszopiclone study showed that eszopiclone did not differ from shallow needling therapy in improving both schizophrenia- and insomnia-related symptoms. Although this study failed to show significant benefits for the use of Z-drug in the treatment of schizophrenia, it showed that short-term use of eszopiclone is an acceptable method for treating persistent insomnia among these patients.

UR - http://www.scopus.com/inward/record.url?scp=85021650647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021650647&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2017.06.063

DO - 10.1016/j.psychres.2017.06.063

M3 - Article

C2 - 28686934

AN - SCOPUS:85021650647

VL - 256

SP - 365

EP - 370

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

ER -